Homocysteine
[Homocysteine ]
EPTIS Ringversuch Nr. 142635 | Letze Änderung 2024-05-21 | URL: https://www.eptis.bam.de/pts142635 https://www.eptis.bam.de/pts142635
| Name des Anbieters | |||||||
| Name des Anbieters | Weqas Weqas | ||||||
| Ansässig in | United Kingdom | ||||||
| Sprache(n) | |||||||
| Anmerkungen | The Homocysteine programme is available as part of a comprehensive suite of programmes to assess and monitor the performance of the Clinical Biochemistry laboratory’s repertoire of both core and esoteric tests used for the diagnosis and monitoring of disease. Homocysteine is tested to aid in the diagnosis of homocysteinuria, as part of a “cardiovascular risk assessment” and to determine folate or vitamin B12-deficiency as blood homocysteine concentration can be raised in both conditions. Three liquid human serum samples with a range of concentrations found in both inborn errors and cardiovascular risk assessment are distributed on a bi-monthly basis. Eighteen samples are distributed annually which consist of endogenous samples along with a panel of linearly related samples produced from donations from healthy volunteers spiked with an exogenous source. The linearly related samples are distributed on a number of occasions over the year to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Liquid human serum samples require no pre-analytical preparation. - Concentration cover in-born errors and cardiovascular risk range. - Includes endogenous samples commutable across all testing platforms. - Linearly related panel covering the pathological range. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/eqa/homocysteine/ or contact@weqas.com | ||||||
| Klassifizierung | |||||||
| Produktgruppen |
Health care / medical devices
|
||||||
| Prüfgebiete |
Medical analysis
|
||||||
| Technische Einzelheiten | |||||||
|
|||||||
| Ringversuchsziele | |||||||
| Zielgruppe des Ringversuchs | The Homocysteine programme is available as part of a comprehensive suite of programmes to assess and monitor the performance of the Clinical Biochemistry laboratory’s repertoire of both core and esoteric tests used for the diagnosis and monitoring of disease. | ||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Weitere Ziele | validation of testing methods | ||||||
| Teilnehmerzahl | |||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/ IEC 17043 |
||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||
| Kosten | |||||||
| Teilnahmegebühr | Fee dependent on number of participating sections and proximetry of testing methods. | ||||||
| Regelmässig durchgeführt | Ja (Frequency: Bimonthly. Samples: 3 x 0.5mL) | ||||||
| Der Ringversuch wird durchgeführt seit | 2004 | ||||||
| Kontaktdaten des Anbieters | |||||||
| Anbieter | Kontaktperson | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.